Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

被引：0
|
作者：
Falcone, Antonietta Pia [1 ]
Sanpaolo, Grazia [1 ]
Rossi, Giovanni [2 ]
Bodenizza, Carlo [1 ]
Carella, Angelo Michele [3 ]
Dell' Olio, Matte [1 ]
Greco, Michele Mario [4 ]
La Sala, Antonio [1 ]
Mantuano, Saverio [1 ]
Melillo, Lorella [5 ]
Merla, Emanuela [4 ]
Nobile, Michele [1 ]
Scalzulli, Potito R. [6 ]
Capalbo, Silvana [7 ]
Cascavilla, Nicola [2 ]
机构：
[1] IRCCS Casa Sollievo della Sofferenza Hosp, Dept Hematol & Stem Cell Transplantat, San Giovanni Rotondo, Italy
[2] IRCCS, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[3] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[4] IRCCS Casa Sollievo Sofferenza, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[5] IRCCS, Hematol & Stem Cell Unit, San Giovanni Rotondo, Italy
[6] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy
[7] Osped Riuniti Azienda Osped Univ, Foggia, Italy
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5032.5032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5032
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [2] BORTEZOMIB, NON-PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE (PAD) REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULTS OF A PILOT STUDY
    Falcone, A.
    Rossi, G.
    Bodenizza, C.
    Carella, A.
    Dell'Olio, M.
    Greco, M.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Scalzulli, P.
    Cascavilla, N.
    HAEMATOLOGICA, 2013, 98 : 604 - 604
  • [3] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Gabriel N. Waterman
    Ori Yellin
    Regina A. Swift
    Russell Mapes
    Benjamin Eades
    Emily Ackerman
    James R. Berenson
    Annals of Hematology, 2011, 90 : 193 - 200
  • [4] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Waterman, Gabriel N.
    Yellin, Ori
    Swift, Regina A.
    Mapes, Russell
    Eades, Benjamin
    Ackerman, Emily
    Berenson, James R.
    ANNALS OF HEMATOLOGY, 2011, 90 (02) : 193 - 200
  • [5] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [6] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    Berenson, J. R.
    Yellin, O.
    Kazamel, T.
    Hilger, J. D.
    Chen, C-S
    Cartmell, A.
    Woliver, T.
    Flam, M.
    Bravin, E.
    Nassir, Y.
    Vescio, R.
    Swift, R. A.
    LEUKEMIA, 2012, 26 (07) : 1675 - 1680
  • [7] Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Moore, Dominic T.
    Winans, Diane
    Orlowski, Robert Z.
    Hurd, David D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07): : 424 - 432
  • [8] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
  • [9] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [10] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    J R Berenson
    O Yellin
    T Kazamel
    J D Hilger
    C-S Chen
    A Cartmell
    T Woliver
    M Flam
    E Bravin
    Y Nassir
    R Vescio
    R A Swift
    Leukemia, 2012, 26 : 1675 - 1680
12345